Atos Medical is a manufacturer of voice prostheses. The company was created out of a desire to make life easier for people living with a stoma of the neck and as of November 2021 serves the needs of more than 100 thousand people.
History
2021: Coloplast bought Atos Medical for €2.2 billion
In mid-November 2021, Coloplast announced the acquisition of voice prosthesis manufacturer Atos Medical for €2.2 billion. After the deal closes, Coloplast plans to manage the company as a separate business with its own identity and brand.
In 2020, Coloplast developed plans to ensure long-term growth through organic and inorganic activities. Strive25's strategy led the company to explore the possibility of acquiring assets to develop its chronic care business, leading to negotiations with Atos Medical. Coloplast's interest in this company reflects the belief that the niche chronic laryngectomy market has much in common with existing chronic patient segments.
In 2016, Atos was bought for €850 million, and reportedly in the summer of 2021, Atos Medical was considering entering the exchange with a valuation of $2 billion or higher, but accepted a purchase offer from Coloplast with a higher valuation. Atos Medical will run on Coloplast infrastructure, resulting in a model designed to support growth through access to commercial and financial opportunities.
 | Our companies have comparable business models, and the acquisition will allow us to use Coloplast's strengths to serve more people living with cervical stoma even better than we do now, "said Britt Meelby Jensen, CEO of Atos Medical, in the announcement of the deal. |  |
The takeover includes recent acquisitions of Atos Medical. In early October 2021, the company completed a deal to acquire TRACOE medical, MC Europe and Kapitex Healthcare, which gave it ownership of tracheostomy tubes in Germany, the Netherlands and the UK.
Vera Coloplast the fact that Atos will be able to continue growth is supported by analysis of the laryngectomy market. According to Coloplast, the market for this procedure is that voice sets are underserved and many patients do not have access to quality products from this grid. The company expects that the increased patient flow and improved quality of treatment will contribute to growth in existing markets with high single-digit performance, and also identified Brazil, Poland, South Korea and China as new markets.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |